MoonLake Immunotherapeutics announces first patients screened in IZAR program

MoonLake Immunotherapeutics (MLTX) announced that the first patients have been screened at U.S. trial sites in its global Phase 3 clinical program, IZAR, evaluating sonelokimab, an investigational Nanobody designed to treat inflammatory disease, in patients with active psoriatic arthritis, PsA. Program will evaluate sonelokimab for a total of 52 weeks, across IZAR-1 and IZAR-2, at sites in the United States, Europe and Latin America, using a design informed by the Phase 2 ARGO trial. The topline primary endpoint readout at week 16 for the program is expected in H1 2026